Objective: The combination of pegylated interferon-α (PEG-IFN) and ribavirin has become a mainstay in the treatment of chronic hepatitis C (CHC). We aimed to evaluate the efficacy of this treatment in patients with CHC, while considering new approaches.
INTRODUCTION
Despite the great success achieved in the fields of virology and diagnostics, several difficulties affect improvements in hepatitis C virus (HCV) infection control and eradication in this new era. With a global prevalence of infection estimated at 2%-3%, it has been calculated that 130-170 million people are infected with HCV. 1 Compared to the global prevalence, Turkey has low rates of HCV infection, which have been estimated to be around 1.0%. The majority of chronic infections are genotype 1b, which range between 75% and 90%.
2 Approximately 75%-85% of people infected with HCV will develop chronic hepatitis, 60%-70% will develop hepatic steatosis or fibrosis, 5%-20% will develop cirrhosis, and in 1%-5% disease will progress to life-threatening complications and hepatocellular carcinoma within 20 years from acute infection. 1 The combination of pegylated interferon-α (PEG-IFN) and ribavirin has been a standard of care for the management of chronic hepatitis C (CHC) and this regimen has significantly contributed to the improvement of long-term clinical outcomes for treated patients. Nevertheless, the rate of treatment success defined by sustained virologic response (SVR) is just 38% to 41% in the genotype 1 infection. 3 We aimed to evaluate the efficacy of double drug treatment with the combination of PEG-IFN and ribavirin in patients with CHC, which is a new era of treatment.
METHODS
This study included a total of 323 patients diagnosed as CHC from the 3 centers (2 in Ordu and 1 in Samsun provinces) in Middle Black Sea region between the years of 2003-2013. Requirements for these patients included PEG-IFN and ribavirin combination treatment and at least 6 months of regular follow-up after therapy. Exclusion criteria included patients who were younger than 18 years old, patients who failed routine follow-up, co-infected with human immunodeficiency virus (HIV), and those with autoimmune hepatitis, decompensated cirrhosis, and pregnancy. Levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, γ-glutamiltransferase, urea, creatinine, bilirubins, albumin, thrombocytes, prothrombin time, activated partial thromboplastin time, and autoantibodies analyses were obtained in all patients prior to the treatment. HBsAg, anti-HCV, anti-HIV tests were studied by Advia Centaur XP device (SIEMENS) with chemilluminesence method. Polymerase chain reaction (PCR) detectable HCV ribonucleic acid (RNA) isolation was performed using "real time" PCR "COBAS AMPLICOR HCV Monitor2.0" (Roche Diagnostics, USA). A total of 237 patients underwent percutaneous liver biopsy and the specimens were evaluated according to Knodell and Ishak scoring systems.
In patients with genotype 1, once-weekly injections of 180 μg of PEG-IFN-2a plus ribavirin were given orally for 48 weeks at a dose of: (i) 1000 mg per day for patients weighing 75 kg or less and (ii) 1200 mg per day for those weighing more than 75 kg. PEG-IFN-2b at a standard dose of 1.5 μg per kilogram of body weight per week, plus oral ribavirin were administered at a dose according to body weight < 65 kg, 800 mg per day; >65 to 85 kg, 1000 mg per day; >85 kg, 1200 mg per day. Anemia was regarded as 2 g/dL decrease from initial level. The ribavirin dose was reduced if hemoglobin (Hb) decreased to <10 g/dL and stopped if Hb decreased to <8.5 g/dL.
After therapy initiated, HCV RNA levels were measured at 4, 12, 24, and 48 weeks. Rapid Virological Response (RVR) was defined as non-detectable for HCV RNA level at 4 weeks. Early Virological Response (EVR) was defined as non-detectable for HCV RNA level or reduction of HCV RNA levels by 2 log or more at 12 weeks of treatment. The end of treatment response (ETR) was defined as continuing non-detectable HCV RNA level at 48 weeks. Patients with an insufficient virologic response at 12 weeks (a detectable HCV RNA level and a decrease of <2 log10 IU from the baseline level) or at 24 weeks (a detectable HCV RNA level) were considered to have treatment failure, and therapy was discontinued. After completion of therapy, HCV RNA levels were obtained at 3, 6, and 12 months. SVR was considered as HCV RNA negativity at the 6th month. Ethical consent was obtained from EPK (Council for Planning of Training and Coordination).
Statistical Analysis
Data were analyzed using SPSS 17.0 program (Chicago, IL, USA) and given as numerical (%), mean ± standard deviation and median (min-max). Chisquare test was used in comparison of cathegorical variables. Mann-Whitney U test was used to compare both groups with data that not represent normal distribution. Student t-test was used in evaluating data with normal distribution. A p-value of less than 0.05 was considered as statistically significant. Fourty-two percent of patients had some aggravating factors leading to increased morbidity like diabetes mellitus, hypertension, heart failure, and chronic obstructive pulmonary disease. However, no statistical differences were noted between SVRs in patients with and without aggravating factors (p > 0.05).
Prior to treatment, ALT and AST levels were median 54 U/L (8-454) and 42 U/L (15-247), respectively. The HCV RNA level had a median of 13×105 IU/ml (983-29×107). The SVR and ETR rates were 58.3% and 75.6%, respectively. In patients with RVR, the SVR rate was 85.1%; whereas in patients with a HCV RNA levels less than 800,000 IU/ml, the SVR rate was 71.2%. The SVR rate did not differ significantly in patients treated with PEG-IFN-2a and 2b (p > 0.05). However, thrombocytopenia was much more detectable in patients receiving PEG-IFN-2a (p < 0.01). Table 1 shows the characteristics of patients with SVR (+) and SVR (-). PEG-IFN-2a or PEG-IFN 2 b and ribavirin were well tolerated. The most frequent side effect was anemia, followed by thrombocytopenia, fatigue, and loss of appetite. transfusion. Dose reduction in interferon treatment was needed in 17 (5%) patients as a result of mostly neutropenia (1%) and thrombocytopenia (1%). The SVR rates were found to be higher in patients who developed hypothyroidism, which was statistically significant (p = 0.03). 
DISCUSSION
In the pivotal clinical trials for registration of PEG-IFN and ribavirin therapy, SVR was achieved in 46% and 40% of patients infected with HCV genotype 1 treated with PEG-IFN-2a or PEG-IFN-2b and ribavirin, respectively. [4] [5] [6] Various factors have been identified that influence response rates, including HCV genotype, body mass index, and co-existent liver disease. Ethnicity was recently noted to impact the treatment responses. Studies conducted in African Americans suggest that these individuals have lower SVR rates when compared to Caucasians, even after adjusting for confounders that could potentially influence treatment response rates. 7, 8 We found the SVR rate to be 58.3%, which was higher than those in the United States. One possible explanation for this may be ethnicity as well as the lower rates of advanced fibrosis and alcohol consumption in our patients. In a study searching the role of ethnicity on treatment responses in Asians and Caucasians with CHC infection, Yan et al. found that Asians infected with HCV genotype 1 achieved a higher SVR rate when compared to a cohort of matched Caucasians. 9 The strongest predictors of SVR are the recently identified genetic polymorphisms located in chromosome 19, which is close to the region coding for IL28B, the HCV genotype, and the stage of fibrosis. Other predictors of response besides the above mentioned, include baseline HCV RNA levels, the dose and duration of therapy, host factors, such as age, insulin resistance, and the stage of fibrosis or co-infection with another hepatotropic virus or with HIV. 10 In patients with favorable predictors for SVR (low baseline HCV RNA, IL28CC, no advanced fibrosis), dual therapy with PEG-IFN/Ribavirin may still be an option. In those patients, a lead-in of 4 weeks PEG-IFN/Ribavirin can identify patients with RVR who can achieve high SVR without adding a protease inhibitor. Patients with low viral load at baseline who achieve an RVR have demonstrated 78-100% SVR with 24 weeks PEG-IFN/Ribavirin dual therapy alone. [11] [12] [13] Similarly, we detected the SVR rate as 85.1% in patients with RVR, whereas the SVR rate was 71.2% in patients with HCV RNA levels less than 800,000 IU/ml. As a favorable predictor, we found the SVR rate at 60% in cases with Ishak fibrosis stage that remained below 4.
In the IDEAL (Individualized Dosing Efficacy vs. Flat Dosing to Assess Optimal Pegylated Interferon Therapy) trial that compared two approved treatment regimens in the United States, which were 41% with PEG-IFN-2a (180 μg/week plus weightbased ribavirin, 1000-1200 mg/day) and 40% with PEG-IFN-2b (1.5 μg/kg/week plus weight-based ribavirin 800-1400 mg/day for 48 weeks) found no significant differences. 3 Similarly, we detected no differences between PEG-IFN-2a and 2b considering SVR.
The most common adverse events are influenza-like symptoms, depression, and the hematologic events of anemia and neutropenia. 3 Several side effects including fatigue and flu-like symptoms in about 60% of patients and depression in 20%-30% may develop. Laboratory abnormalities such as neutropenia, anemia, and thrombocytopenia were the most frequent indicators for dose reduction. Thus, approximately 25% of patients required at least one dose reduction for laboratory abnormalities during therapy. 14 The main side effect of ribavirin is hemolytic anemia as this complication may frequently result in ribavirin dose reduction or even discontinuation, which may significantly affect the overall SVR, especially in patients with HCV genotype 1. 10 Anemia was detected in 75% in our patients, being the most frequent side effect; however, 20% of patients needed dose reduction. On follow-up, treatment was discontinued in 31 (9%) patients due to anemia. It is an interesting finding that patients with considerably higher rates (75%) of anemia represented somewhat lower rates (9%) of treatment discontinuation compared other studies. 10 In general, other side effects were detected in similar rates. Because the dose arrangement might be needed, potential side effects must be monitored closely during therapy.
Interferon (IFN) has immuno-modulatory properties, and treatment can induce autoimmune phenomena. The most frequent problem is the development of autoimmune thyroiditis. In most cases, thyroiditis starts with hyperthyroidism that later becomes hypothyroidism. Autoimmune thyroiditis has been reported in up to 20% of patients under or after IFN based therapies. 10 We found autoimmune thyroiditis in 12% of patients, and SVR rates to be higher in patients who developed hypothyroidism. This may be due to strong immune response making SVR rates higher and destroying thyroid gland. Mauss et al. revealed thyroid dysfunction that is triggered during PEG IFN-2b plus ribavirin treatment was an independent predictor to indicate higher SVR rates in CHC patients infected with genotype 1. 15 In conclusion, dual therapy with PEG-IFN/ ribavirin is still an option in treating CHC infection, especially when considering the costs and side effects as well as patients therapy toleration. On the other hand, the shortcomings of PEG-IFN/ribavirin therapy for HCV eradication is hardly expected in patients with high baseline viral loads, older age, and advanced fibrosis. Treatment regimens including protease inhibitor or newer treatment modalities should be administered.
